Study Links Chantix to Suicide Risk, but FDA Disagrees

Nov. 3, 2011 -- Just over a week after federal health officials released a report finding no evidence of an increased risk of serious psychiatric problems in users of the anti-smoking drug Chantix, a new study comes to the opposite conclusion.

Investigators who were the first to link the drug to suicidal behavior and depression say the new research suggests that Chantix may be too risky to use as a first treatment for smoking cessation and should only be used when other treatments have failed.

Representatives of FDA and Pfizer, the drug's manufacturer, strongly disagree with the new study findings.

Stronger Warning Needed?

The researchers found that 90% of all reported suicides related to anti-smoking treatments from 1998 to 2010 involved Chantix, even though the drug has only been on the market in the U.S. for about four years.

"We believe this drug is not suitable for use as a first choice for people who are trying to stop smoking," study researcher Thomas J. Moore tells WebMD. Moore is a senior scientist with Safe Medicine Practices, an independent drug safety research group.

The researchers say that use of Chantix was eight times more likely to result in suicidal behavior or depression than use of nicotine-replacement gums, patches, lozenges, and inhalers.

They are asking the FDA to revise its labeling for Chantix to show this increased risk. But an FDA official is calling the researchers' conclusions misleading.

The new study was published online this week and appears in the November issue of PLoS One.